Abstract:IntroductionGliomas are the most common malignant cancer affecting the CNS, accounting for 60% of primary brain tumors (DeAngelis, 2001; Yiu&He, 2006).The majority of gliomas in adults are highly malignant with a poor prognosis, in particular with high-grade tumors such as glioblastoma multiforme.Current therapy with surgery, radiation, and chemotherapy rarely, if ever, cures the disease and infrequently prolongs life for 1 year (Curran et al., 1993;Bao et al., 2006).Additional considerations focus on developing novel modalities to increase anti-glioma effects and decrease side-effects.Differentiation therapy, using agents that modify cancer cell differentiation, has shown promise in the spectrum of agents used against tumors (Leszczyniecka et al., 2001).Wang and Chen demonstrated the clinical application for differentiation therapy by introducing all-trans-retinoic acid to clinical use for the treatment of acute promyelocytic leukemia (APL) (Huang et al., 1988; Wang&Chen, 2000).Notably, the inorganic toxicant arsenic trioxide (As2O3), a well known environmental carcinogen, has been also proven to be an effective drug in the treatment of APL patients by triggering apoptosis and differentiation of APL cells in a dose-dependent manner (Shen et al., 1997;Kinjo et al., 2000).Such excellent effects, however, were not reproduced in other hematological and, particularly, solid tumors.Differentiation agents for malignant gliomas remain a real challenge.In this chapter, we base on our research and mainly discuss proteins or molecules capable of inducing differentiation via targeting cAMP/cAMP-dependent protein kinase A (PKA) signal pathway and crucial factors such as glycogen synthase kinase-3 (GSK-3 ) and hypoxia-inducible factor-1 (HIF-1 ) determining the efficiency of these drugs.Although agents for differentiation therapy have wide application prospect, their real therapeutic potentiality remains to be further realized. The molecular mechanism for differentiation therapy of malignant glioma2.1 cAMP/PKA signaling activators induce malignant glioma cell differentiation cAMP/PKA signaling has been reported to play important roles in multiple physiological processes, including growth, differentiation, gene regulation, and apoptosis (Walsh&Van Patten, 1994).Disruption of the PKA catalytic subunit causes destabilization of the diploid cell cycle, and the cells start meiosis under conditions repressive for wild-type meiosis (Maeda et al., 1994).Ample evidences indicate that cAMP-elevating stimuli such as Nwww.intechopen.com

Cyclic AMP-dependent Regulation of Differentiation of Rat C6 Glioma Cells by Panaxydol

Growth Inhibition and Induction of Differentiation by Panaxydol in Rat C6 Glioma Cells

Phosphatidylinositol 3-Kinase Activity is Required for the Induction of Differentiation in C6 Glioma Cells by Panaxydol.

Induction of differentiation by panaxydol in human hepatocarcinoma SMMC-7721 cells via cAMP and MAP kinase dependent mechanism.

Induction of Apoptosis in Rat C6 Glioma Cells by Panaxydol

Adenosine 3':5'-Cyclic Monophosphate Induces Differentiation of Glioma Cells : an Experimental Study

The effects of dexamethasone on cyclic adenosine 3',5'-monophosphate induced differentiation of glioma cells

Molecular Mechanism of Panaxydol on Promoting Axonal Growth in PC12 Cells

Change of Morphology and Cytoskeletal Protein Gene Expression during Dibutyryl cAMP-induced Differentiation in C6 Glioma Cells

Panaxynol induces neurite outgrowth in PC12D cells via cAMP- and MAP kinase-dependent mechanisms.

Disruption of β-catenin-mediated negative feedback reinforces cAMP-induced neuronal differentiation in glioma stem cells

Transcriptional and post-transcriptional down-regulation of cyclin D1 contributes to C6 glioma cell differentiation induced by forskolin.

Panaxydol inhibits the proliferation and induces the differentiation of human hepatocarcinoma cell line HepG2.

The Molecular Mechanism for Differentiation Therapy of Malignant Glioma

MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway.

Induction of neural differentiation in rat C6 glioma cells with taxol

Growth Inhibition of 20(S)-Protopanaxadiol on Prostate Cancer Cells RM-1 in Mice and Its Mechanism

Differentiation of SWO-38 glioma cells induced by CDA-2 is mediated by peroxisome proliferator-activated receptor gamma.

Synergistic effects of cyclic AMP and nerve growth factor on neurite outgrowth and microtubule stability of PC12 cells.

[Effect of all-trans-retinoic acid on C6 glioma cell proliferation and differentiation].

Regulation of Cytoskeleton Organization and Paxillin Dephosphorylation by Camp: STUDIES ON MURINE Y1 ADRENAL CELLS